HIV PrEP and hormones: small study aims to Fine-Tune dosing for transgender women
NCT ID NCT04760691
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial from Johns Hopkins University enrolled 13 transgender women to see how the HIV prevention drug Truvada interacts with feminizing hormones like estrogen. Participants took Truvada alone and then with added hormones or a testosterone blocker. The goal was to measure drug levels in blood and tissues to find the best dosing strategy. The study did not test whether Truvada actually prevents HIV, but rather how hormones might affect its concentration in the body.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Truvada (tenofovir disoproxil fumarate/emtricitabine) with or without leuprolide or estradiol
What this could lead to
If successful, this could help doctors determine the right dose of HIV PrEP for transgender women taking feminizing hormones, improving HIV prevention in this group.
What could go wrong
This was a very small, early-phase trial with only 13 participants, so results may not apply to everyone. It focused on drug levels, not actual HIV prevention, so more research is needed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Johns Hopkins School of Medicine Drug Development Unit
Baltimore, Maryland, 21287, United States